6505--RX - PYLARIFY (PIFLUFOLASTAT F 18 INJECTION) Brand name or Equal

SOL #: 36C24226Q0246Combined Synopsis/Solicitation

Overview

Buyer

Veterans Affairs
Veterans Affairs, Department Of
242-NETWORK CONTRACT OFFICE 02 (36C242)
ALBANY, NY, 12208, United States

Place of Performance

Place of performance not available

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

Drugs And Biologicals (6505)

Set Aside

Total Small Business Set-Aside (FAR 19.5) (SBA)

Timeline

1
Posted
Dec 31, 2025
2
Last Updated
Apr 2, 2026
3
Submission Deadline
Mar 12, 2026, 2:00 PM

Qualification Details

Fit reasons
  • NAICS alignment with historical contract wins in similar service areas.
  • Scope strongly matches core technical capabilities and delivery model.
Risks
  • Past performance thresholds may require one additional teaming partner.
  • Potential clarification needed on staffing minimums before bid/no-bid.
Next steps

Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.

Quick Summary

The Department of Veterans Affairs (VA), Network Contracting Office 2, has issued a Combined Synopsis/Solicitation for the procurement of Pylarify (Piflufolastat F 18 Injection) or an equal radiopharmaceutical product. This requirement is for diagnostic PET imaging at multiple VA Medical Centers (VAMCs) within VISN 2 South. This acquisition is a Total Small Business Set-Aside. Offers are due by March 12, 2026, at 10:00 AM EDT.

Scope of Work & Requirements

The solicitation seeks a diagnostic PET radiopharmaceutical, specifically Pylarify (piflufolastat F-18 intravenous) or an equivalent product, for daily delivery of 9.0 mCi doses to specified VAMCs, Monday through Friday before 12:00 PM (noon). Key salient characteristics for an equal product include:

  • Half-life greater than 100 minutes.
  • High tumor-to-background ratio and sensitivity of 85% or more.
  • FDA Approved, high spatial resolution.
  • Contains Fluorine-18 (F-18) radiolabeled prostate-specific membrane antigen inhibitor.
  • Sterile, non-pyrogenic, clear colorless solution for intravenous injection.
  • Radiochemical purity of at least 95% up to 10 hours post-synthesis.
  • Specific activity of at least 1000mCi/µmol at time of administration.
  • Ability to bind to cells expressing prostate-specific membrane antigen (PSMA).
  • Must not contain gallium-68.

The contractor must possess a Nuclear Regulatory Commission License and comply with DOT, NRC/NHPP, FDA, OSHA, and USP 797 regulations. Copies of licenses and certifications are required with proposals. Additional requirements include providing a quality control manual, MSDS sheets, current package inserts, and assigning a sales representative for each VAMC. Ordering will be available via Phone, Fax, and Web-based methods (Web-based preferred).

Contract Details

  • Contract Type: Firm-Fixed-Price
  • Period of Performance: April 1, 2026, to March 31, 2027
  • Product Service Code (PSC): 6505 (Drugs And Biologicals)
  • NAICS Code: 325412 (Pharmaceutical Preparation Manufacturing)
  • Size Standard: 1300 Employees

Submission & Evaluation

  • Offer Submission Deadline: March 12, 2026, 10:00 AM EDT
  • Questions Deadline: March 9, 2026, 10:00 AM EDT
  • Evaluation Factors: Technical, Past Performance, Price, and Veterans Participation Credit.
  • Offer Acceptance Period: 60 calendar days from the offer due date.
  • Submission Format: Proposals must be submitted electronically in PDF or Microsoft Excel format.

Contact Information

People

Points of Contact

Aleta JennetteContracting OfficerPRIMARY

Files

Files

Download
Download
View
View
Download
View
Download
Download

Versions

Version 6
Pre-Solicitation
Posted: Apr 2, 2026
View
Version 5
Award Notice
Posted: Apr 2, 2026
View
Version 4Viewing
Combined Synopsis/Solicitation
Posted: Apr 2, 2026
Version 3
Combined Synopsis/Solicitation
Posted: Mar 5, 2026
View
Version 2
Pre-Solicitation
Posted: Mar 4, 2026
View
Version 1
Sources Sought
Posted: Dec 31, 2025
View